AZ 628

Research use only, not for human use.

AZ 628(AZ-628, AZ628) is a potent and selective B-Raf inhibitor with IC50s of 2.14 uM and 0.19 uM for wt Braf and Braf V600E respectively.

AZ 628(AZ-628, AZ628) is a potent and selective B-Raf inhibitor with IC50s of 2.14 uM and 0.19 uM for wt Braf and Braf V600E respectively.

AZ 628 reduces activities of preactivated B-Raf, B-RafV600E, and c-Raf-1 in in vitro kinase assays, with IC50 values of 105, 34 and 29 nM, respectively. AZ 628 also inhibits activation of number of tyrosine protein kinases including VEGFR2, DDR2, Lyn, Flt1, FMS and others. AZ 628 inhibits anchorage-dependent and -independent growth, causes cell cycle arrest, and induces apoptosis in colon and melanoma cell lines harboring B-RafV600E mutation. AZ 628 suppresses growth in cells expressing K-RASG13D. Inhibition of RAF with AZ 628 suppresses MEK and ERK phosphorylation. AZ 628 selectively affects viability in K-RAS mutant cells.

——

AZ-628 | AZ628

MAPK/ERK Signaling

Raf

B-Raf| B-Raf (V600E)| C-Raf-1

Cancer

——

878739-06-1

451.5197

C27H25N5O2

>98% (HPLC)

10 mM in DMSO

O=C(NC1=CC=C(C)C(NC2=CC3=C(N=CN(C)C3=O)C=C2)=C1)C4=CC=CC(C(C)(C#N)C)=C4

Benzamide, 3-(1-cyano-1-methylethyl)-N-[3-[(3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-methylphenyl]-

(-20℃)

With Ice Pack

≥ 2 years